Lasa Supergenerics share price
High risk
You have to be logged in to add this to Watchlist.- ₹13.04(-1.21%)June 13, 2025 15:27:32 PM IST
- NSE
- BSE
- Vol : 293.96K (NSE + BSE)Last 20 day avg : 376.18 K
Lasa Supergenerics is trading -1.21% lower at Rs 13.04 as compared to its last closing price. Lasa Supergenerics has been trading in the price range of 13.30 & 12.54. Lasa Supergenerics has given -48.19% in this year & 1.00% in the last 5 days. The company posted a net profit of -14.29 Crores in its last quarter.Listed peers of Lasa Supergenerics include Vista Pharmaceuticals (1.69%), Vivo Bio Tech (0.08%), Lasa Supergenerics (-1.21%).The Mutual Fund holding in Lasa Supergenerics was at -% in . The MF holding has - from the last quarter. The FII holding in Lasa Supergenerics was at 0.01% in 30 Sep 2024. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Key Metrics
Updated on Jun 13, 2025, 08:05 PM UTC
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- P/BLower than historical values0.79The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values0.00Price-to-earnings ratio based on trailing 12-month earnings
- BetaHigh volatility1.27Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To Equity-The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Lasa Supergenerics News
Lasa Supergenerics Financials
Financials
View allFinancials include key reports like the Profit & Loss Statement (P&L), Balance Sheet, and Cash Flow Statement, providing insights into a company's performance, financial health, and liquidity
- Income
- Balance Sheet
- Cash Flow
Loading...
Units in the chart are in crores
Insights
- Financial
- Valuation
Company is not profitable
The company's revenue grew in March quarter by 71.53% from Rs 39.14 crore to Rs 22.82 crore, year-on-year- The company has reduced its March quarter loss by 6.59% from Rs 15.30 crore to Rs 14.29 crore, year-on-year
- Earnings are insufficient to cover the interest expenses on outstanding debt
Lasa Supergenerics Technical Analysis
Pivot Level - classic
Key price levels (support and resistance) calculated using the previous day's high, low, and close, aiding in technical analysis and trading decisions
- R1
- 15.89
- R2
- 16.99
- R3
- 18.45
Pivot14.43
- S1
- 13.33
- S2
- 11.87
- S3
- 10.77
Short Term
Considers price movement over the last 1-2 weeks
Not Available
Long Term
Considers price movement over the last 6 months
Not Available
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Trends unavailable at the moment.
Lasa Supergenerics Peers
Return Comparison
Peers Comparison
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Vista Pharmaceuticals | Moderately Bullish | 11.44 | 1.69 | 70.41 | - | 0.31 | - | 5.24 |
| Vivo Bio Tech | Bearish | 38.09 | 0.08 | 61.45 | 8.06 | 0.73 | - | 44.85 |
| Lasa Supergenerics | Bearish | 13.04 | -1.21 | 65.34 | - | 0.79 | - | - |
| Vasundhara Rasayans | Moderately Bearish | 209.90 | -0.31 | 66.76 | 15.16 | 1.81 | 0.99 | - |
| Jeevan Scientific Technology | Moderately Bearish | 40.10 | 2.40 | 63.50 | 977.00 | 1.24 | - | 31.22 |
Lasa Supergenerics Shareholding
View AllShareholding Pattern
Breakdown of a company's ownership structure, showing stakes held by Promoters, Mutual Funds, FII(s) & Others.
Shareholding pattern for Lasa Supergenerics is currently unavailable
Please check back later.
Shareholding Insights
- Pledged found - Promoter(s) have pledged 20.66% of shares.
- Pledging Flat - Promoter(s) pledging has not increased in last quarter.
- Promoter(s) holds a high stake in the company at 53.65%
- FIIs are not invested in this company
- Mutual Funds are not invested in this company.
Lasa Supergenerics Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-05-28 | Audited Results |
| 2025-05-26 | Audited Results |
| 2025-02-13 | Quarterly Results |
| 2025-01-28 | Others |
| 2025-01-24 | To consider issue of Warrants |
About the company Lasa Supergenerics
- IndustryBiotechnology & Drugs
- ISININE670X01014
- BSE Code540702
- NSE CodeLASA
Lasa Supergenerics Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (API) bulk drugs products. The Company is engaged in the business of manufacturing, trading, producing, processing, preparing, and treating chemicals, API, pharmaceuticals, drugs, and others. It specializes in catalyst chemistry and manufactures anthelmintic/ veterinary API products with production capabilities and product categories in India. The Company's products include API products, other API products, animal feed ingredients and reagents for therapeutic use. Its API products include Fenbendazole, Toldimphos sodium, Cyromazine, Albendazole, Riclabendazole, Rafoxanide, Ornidazole, 2,6-Diiodo-4-Nitrophenol, Ricobendazole, Oxfendazole, Closantel Base, Closantel sodium, Nitroxynil, Halquinol, and Oxyclozanide. The Company's manufacturing facility is located in Chiplun, Maharashtra.
Lasa Supergenerics Share Price FAQs
Lasa Supergenerics is trading at 13.04 as on Fri Jun 13 2025 09:57:32. This is -1.21% lower as compared to its previous closing price of 13.20.
The market capitalization of Lasa Supergenerics is 65.34 Cr as on Fri Jun 13 2025 09:57:32.
The 52 wk high for Lasa Supergenerics is 33.49 whereas the 52 wk low is 12.96
Lasa Supergenerics can be analyzed on the following key metrics -
- TTM P/E:
- Sector P/E: -
- Dividend Yield: 0.00%
- D/E ratio: 0.03
Lasa Supergenerics reported a net profit of -14.76 Cr in 2025.
Quick Links